GELS
Gelteq Limited Ordinary SharesNASDAQHealthcare$0.68-8.04%ClosedMarket Cap: $6.2M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.00
P/S
56.09
EV/EBITDA
-3.73
DCF Value
$-0.27
FCF Yield
-66.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-3317.7%
Net Margin
-4011.9%
ROE
-43.0%
ROA
-30.9%
ROIC
-27.4%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| FY 2025 | $165.6K | $-6.6M | $0.00 |
| Q4 2024 | $0.00 | $-1.1M | $0.00 |
| FY 2024 | $0.00 | $-3.5M | $0.00 |
| Q3 2024 | $0.00 | $-727.4K | $0.00 |
Trading Activity
Insider Trades
View AllWYNNE Paul Michaelofficer
SellWed Mar 18
Szewach Simon Hdirector
SellWed Mar 18
Szewach Simon Hdirector
SellWed Mar 18
Karp Bradley Glennofficer: Head of Sales and Marketing
SellWed Mar 18
Givoni Nathan Jofficer: Chief Executive Officer
SellWed Mar 18
Company Info
Sector
Healthcare
Industry
—
Country
AU
Exchange
NASDAQ
Beta
-0.32
Gelteq Limited focuses on developing and commercializing a gel-based delivery system for humans and animals. It offers white label gel-based delivery solutions for prescription drugs, over-the-counter products, nutraceuticals and sports, pet care, and other products. The company was incorporated in 2017 and is headquartered in Caulfield, Australia.